vs
Side-by-side financial comparison of ADMA BIOLOGICS, INC. (ADMA) and Wheels Up Experience Inc. (UP). Click either name above to swap in a different company.
Wheels Up Experience Inc. is the larger business by last-quarter revenue ($183.8M vs $139.2M, roughly 1.3× ADMA BIOLOGICS, INC.). ADMA BIOLOGICS, INC. runs the higher net margin — 35.5% vs -15.7%, a 51.2% gap on every dollar of revenue. On growth, ADMA BIOLOGICS, INC. posted the faster year-over-year revenue change (18.4% vs -10.2%). ADMA BIOLOGICS, INC. produced more free cash flow last quarter ($34.6M vs $-58.3M). Over the past eight quarters, ADMA BIOLOGICS, INC.'s revenue compounded faster (30.4% CAGR vs -3.4%).
ADMA Biologics Inc. is a biopharmaceutical enterprise focused on the research, development, manufacturing and commercialization of specialty plasma-derived immunoglobulin therapies. It primarily operates in the United States, catering to patients with primary immunodeficiency and other immune-related disorders, healthcare providers and medical institutions across its core immune health therapeutic segment.
Wheels Up is a provider of "on demand" private aviation in the United States and one of the largest private aviation companies in the world. It was founded in 2013 by Kenny Dichter, using a membership/on-demand business model. Wheels Up members can book private aircraft from the company fleet and third-party operators using a mobile application.
ADMA vs UP — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $139.2M | $183.8M |
| Net Profit | $49.4M | $-28.9M |
| Gross Margin | 63.8% | 14.3% |
| Operating Margin | 45.1% | -0.9% |
| Net Margin | 35.5% | -15.7% |
| Revenue YoY | 18.4% | -10.2% |
| Net Profit YoY | -55.9% | 67.0% |
| EPS (diluted) | $0.20 | $-0.04 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $139.2M | $183.8M | ||
| Q3 25 | $134.2M | $185.5M | ||
| Q2 25 | $122.0M | $189.6M | ||
| Q1 25 | $114.8M | $177.5M | ||
| Q4 24 | $117.5M | $204.8M | ||
| Q3 24 | $119.8M | $193.9M | ||
| Q2 24 | $107.2M | $196.3M | ||
| Q1 24 | $81.9M | $197.1M |
| Q4 25 | $49.4M | $-28.9M | ||
| Q3 25 | $36.4M | $-83.7M | ||
| Q2 25 | $34.2M | $-82.3M | ||
| Q1 25 | $26.9M | $-99.3M | ||
| Q4 24 | $111.9M | $-87.5M | ||
| Q3 24 | $35.9M | $-57.7M | ||
| Q2 24 | $32.1M | $-97.0M | ||
| Q1 24 | $17.8M | $-97.4M |
| Q4 25 | 63.8% | 14.3% | ||
| Q3 25 | 56.3% | 6.8% | ||
| Q2 25 | 55.1% | 8.3% | ||
| Q1 25 | 53.2% | 10.8% | ||
| Q4 24 | 53.9% | 13.9% | ||
| Q3 24 | 49.8% | 13.9% | ||
| Q2 24 | 53.6% | 2.3% | ||
| Q1 24 | 47.8% | -0.6% |
| Q4 25 | 45.1% | -0.9% | ||
| Q3 25 | 38.0% | -33.1% | ||
| Q2 25 | 35.1% | -31.4% | ||
| Q1 25 | 30.4% | -45.5% | ||
| Q4 24 | 32.6% | -26.0% | ||
| Q3 24 | 33.1% | -21.6% | ||
| Q2 24 | 36.6% | -40.3% | ||
| Q1 24 | 26.7% | -42.9% |
| Q4 25 | 35.5% | -15.7% | ||
| Q3 25 | 27.1% | -45.1% | ||
| Q2 25 | 28.1% | -43.4% | ||
| Q1 25 | 23.4% | -55.9% | ||
| Q4 24 | 95.2% | -42.7% | ||
| Q3 24 | 30.0% | -29.8% | ||
| Q2 24 | 29.9% | -49.4% | ||
| Q1 24 | 21.7% | -49.4% |
| Q4 25 | $0.20 | $-0.04 | ||
| Q3 25 | $0.15 | $-0.12 | ||
| Q2 25 | $0.14 | $-0.12 | ||
| Q1 25 | $0.11 | $-0.14 | ||
| Q4 24 | $0.45 | $-0.13 | ||
| Q3 24 | $0.15 | $-0.08 | ||
| Q2 24 | $0.13 | $-0.14 | ||
| Q1 24 | $0.08 | $-0.14 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $87.6M | $133.9M |
| Total DebtLower is stronger | $72.1M | $671.3M |
| Stockholders' EquityBook value | $477.3M | $-392.1M |
| Total Assets | $624.2M | $968.8M |
| Debt / EquityLower = less leverage | 0.15× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $87.6M | $133.9M | ||
| Q3 25 | $61.4M | $125.3M | ||
| Q2 25 | $90.3M | $107.0M | ||
| Q1 25 | $71.6M | $171.8M | ||
| Q4 24 | $103.1M | $216.4M | ||
| Q3 24 | $86.7M | $115.9M | ||
| Q2 24 | $88.2M | $141.5M | ||
| Q1 24 | $45.3M | $180.9M |
| Q4 25 | $72.1M | $671.3M | ||
| Q3 25 | $72.4M | $766.5M | ||
| Q2 25 | — | $770.5M | ||
| Q1 25 | — | $765.8M | ||
| Q4 24 | $72.3M | $761.3M | ||
| Q3 24 | — | $596.9M | ||
| Q2 24 | — | $597.4M | ||
| Q1 24 | — | $603.2M |
| Q4 25 | $477.3M | $-392.1M | ||
| Q3 25 | $431.2M | $-374.5M | ||
| Q2 25 | $398.3M | $-347.8M | ||
| Q1 25 | $373.4M | $-288.1M | ||
| Q4 24 | $349.0M | $-202.1M | ||
| Q3 24 | $231.9M | $-117.7M | ||
| Q2 24 | $188.3M | $-72.2M | ||
| Q1 24 | $153.7M | $936.0K |
| Q4 25 | $624.2M | $968.8M | ||
| Q3 25 | $568.7M | $973.0M | ||
| Q2 25 | $558.4M | $1.0B | ||
| Q1 25 | $510.6M | $1.1B | ||
| Q4 24 | $488.7M | $1.2B | ||
| Q3 24 | $390.6M | $1.0B | ||
| Q2 24 | $376.4M | $1.1B | ||
| Q1 24 | $350.9M | $1.2B |
| Q4 25 | 0.15× | — | ||
| Q3 25 | 0.17× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 0.21× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | 644.43× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $35.6M | $-18.4M |
| Free Cash FlowOCF − Capex | $34.6M | $-58.3M |
| FCF MarginFCF / Revenue | 24.8% | -31.7% |
| Capex IntensityCapex / Revenue | 0.8% | 21.7% |
| Cash ConversionOCF / Net Profit | 0.72× | — |
| TTM Free Cash FlowTrailing 4 quarters | $27.8M | $-259.9M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $35.6M | $-18.4M | ||
| Q3 25 | $13.3M | $-37.1M | ||
| Q2 25 | $21.1M | $-62.9M | ||
| Q1 25 | $-19.7M | $-47.9M | ||
| Q4 24 | $50.2M | $37.9M | ||
| Q3 24 | $25.0M | $-16.9M | ||
| Q2 24 | $45.6M | $-25.2M | ||
| Q1 24 | $-2.2M | $-73.8M |
| Q4 25 | $34.6M | $-58.3M | ||
| Q3 25 | $-1.1M | $-60.4M | ||
| Q2 25 | $18.7M | $-78.6M | ||
| Q1 25 | $-24.4M | $-62.6M | ||
| Q4 24 | $47.5M | $-70.2M | ||
| Q3 24 | $24.0M | $-21.9M | ||
| Q2 24 | $43.6M | $-30.8M | ||
| Q1 24 | $-4.6M | $-77.8M |
| Q4 25 | 24.8% | -31.7% | ||
| Q3 25 | -0.8% | -32.6% | ||
| Q2 25 | 15.3% | -41.5% | ||
| Q1 25 | -21.2% | -35.3% | ||
| Q4 24 | 40.4% | -34.3% | ||
| Q3 24 | 20.0% | -11.3% | ||
| Q2 24 | 40.7% | -15.7% | ||
| Q1 24 | -5.6% | -39.5% |
| Q4 25 | 0.8% | 21.7% | ||
| Q3 25 | 10.7% | 12.5% | ||
| Q2 25 | 2.0% | 8.3% | ||
| Q1 25 | 4.1% | 8.3% | ||
| Q4 24 | 2.3% | 52.8% | ||
| Q3 24 | 0.9% | 2.6% | ||
| Q2 24 | 1.9% | 2.9% | ||
| Q1 24 | 2.9% | 2.0% |
| Q4 25 | 0.72× | — | ||
| Q3 25 | 0.36× | — | ||
| Q2 25 | 0.62× | — | ||
| Q1 25 | -0.73× | — | ||
| Q4 24 | 0.45× | — | ||
| Q3 24 | 0.70× | — | ||
| Q2 24 | 1.42× | — | ||
| Q1 24 | -0.12× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ADMA
| ADMA Bio Manufacturing Segment | $123.1M | 88% |
| Other | $16.0M | 12% |
UP
Segment breakdown not available.
